Vanda Pharmaceuticals Inc (STU:VM4)
€ 4.324 +0.31 (+7.72%) Market Cap: 261.29 Mil Enterprise Value: 133.56 Mil PE Ratio: 0 PB Ratio: 1.51 GF Score: 70/100

Q2 2026 Vanda Pharmaceuticals Inc Earnings Call Transcript

Aug 05, 2026 / 08:30PM GMT
Release Date Price: €4.38 (-4.95%)
Operator

Good afternoon and welcome to the second quarter 2026 Vanda Pharmaceuticals Incorporated earnings conference call. I am France, and I'll be the operator assisting you today. (Operator Instructions) Thank you.

I would now like to turn the call over to Vanda's Chief Financial Officer, Kevin Moran. Please go ahead.

Kevin Moran
Vanda Pharmaceuticals Inc - Senior Vice President, Chief Financial Officer and Treasurer

Thank you, France. Good afternoon and thank you for joining us to discuss Vanda Pharmaceuticals' second-quarter 2026 performance. Our second-quarter 2026 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website. Joining me on today's call is Dr. Mihael Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board, and Daniel M. McGuire, our General Counsel. Following my introductory remarks, Mihael

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot